Background: S-1 is a combination of tegafur [metabolized to 5-fluorouracil (5-FU)] with the modulators gimeracil (5-chloro-2,4-dihydroxypyridine) and oteracil potassium. 5-Chloro-2,4-dihydroxypyridine maintains plasma 5-FU concentrations by inhibiting dihydropyrimidine dehydrogenase, a pyrimidine catabolism enzyme that degrades 5-FU. As 50% of 5-chloro-2,4-dihydroxypyridine is excreted in urine, renal insufficiency may increase its blood level, increasing 5-FU concentrations. We investigated whether special dose modification is needed in the presence of renal insufficiency. Objective: We compared steady state pharmacokinetics of 5-FU for the initial S-1 dose and reduced doses in patients with head and neck cancer requiring dose reduction due to renal and non-renal toxicities. Methods: Chemoradiotherapy with S-1 and cisplatin was administered every 5 weeks for two courses with a radiation dose totaling 70 Gy over 33-35 fractions. Two additional courses of adjuvant chemotherapy were administered in the case of an objective response. The S-1 and/or cisplatin dose was reduced in response to renal, hematologic or other toxicities. The primary endpoint was the change in area under the plasma concentration-versus-time curve from time 0-10 hours (5-FU AUC ss 0-10 ) between the initial and reduced S-1 doses. Results: Although the mean 5-FU levels in patients with non-renal toxicities significantly decreased between the full and reduced dose, the full-dose and reduced-dose mean maximum 5-FU plasma concentrations at steady state (C ss max ) and AUC ss 0-10 in patients with renal insufficiency were similar. Conclusions: Standard S-1 dose reduction for renal toxicity did not result in a significant decrease in 5-FU levels at steady state. A greater reduction to lower plasma 5-chloro-2,4-dihydroxypyridine may be necessary in patients with renal insufficiency.
Introduction
S-1 is a novel oral anticancer agent, which consists of tegafur (FT) and two modulators, 5-chloro-2,4-dihydroxypyridine (gimeracil, CDHP) and oteracil potassium, at a molar ratio of 1:0.4:1. The combination of these three agents is based on the biochemical modulation of 5-fluorouracil (5-FU), which is metabolized from FT. CDHP increases 5-FU concentration by inhibiting dihydropyrimidine dehydrogenase (DPD), a pyrimidine catabolism enzyme that degrades 5-FU (1) . As 50% of CDHP is excreted in the urine, however, renal dysfunction and the resulting increase in CDHP concentration can increase the inhibition of DPD, resulting in an increase in 5-FU concentrations (2, 3) . No study has compared the pharmacokinetics of 5-FU between the initial S-1 dose and reduced doses in patients with locally advanced head and neck cancer requiring dose reduction.
S-1 was approved for use in head and neck cancer in Japan in 2001. The efficacy and toxicity of S-1 plus cisplatin combination therapy in the treatment of squamous cell carcinoma of the head and neck (SCCHN) were demonstrated in a Phase 1 study (4) and the efficacy and safety of chemoradiotherapy (CRT) with the same S-1 plus cisplatin combination for SCCHN were investigated in a phase II trial (5) . The results revealed promising efficacy with acceptable toxicity. We sought to further characterize the toxicity profile of CRT with the S-1/cisplatin combination, especially after the development of renal toxicity.
Patients and methods
Financial support for 5-FU measurements and pharmacokinetic analysis was provided by Taiho Pharmaceutical Co. Ltd.
Patient selection
The study was conducted under a prospective design at a single institution. Eligibility required histologically or cytologically confirmed SCCHN with unresectable locally advanced disease. Patients had to meet all of the following inclusion criteria: (i) primary lesion located in the nasopharynx, nasal cavity, paranasal sinuses, oropharynx, hypopharynx, larynx, oral cavity or salivary gland fulfilling at least one of the following the conditions: (a) primary lesion or cervical lymph node metastasis to the carotid space (bordering/encasing the artery), skull base or cervical vertebra and/ or its surrounding musculature; (b) T4 primary lesion located in the oropharynx; (ii) age between 20 and 75 years; (iii) ECOG performance status of 0 or 1; (iv) sufficient organ function and (v) normal electrocardiogram.
Exclusion criteria included fistulas, distant metastases, active bacterial or fungal infection; simultaneous or metachronous (within 5 years) second cancers except carcinoma in situ or intramucosal tumor (e.g. gastric or esophageal cancer curable by endoscopic mucosal resection); pregnancy or lactation; active gastrointestinal bleeding; pleural or pericardial effusion; massive ascites; history of severe heart disease, heart failure, myocardial infarction within 6 months, or angina pectoris attack within 6 months; cerebrovascular accident within 6 months; diabetes mellitus treated with insulin or poorly controlled; poorly controlled hypertension; chronic pancreatitis; positive HBs antigen; inability to refrain from smoking and drinking during treatment; and requirement for systemic steroids.
The study protocol was approved by the Institutional Review Board (IRB) of the National Cancer Center Hospital East (approval number 21-180), and written informed consent to treatment was obtained from all patients before the initiation of treatment.
This trial was registered with the University Hospital Medical Information Network (No. UMIN000025205).
Treatment
Chemotherapy Treatment followed the JCOG0706 protocol consisting of CRT, adjuvant chemotherapy and salvage surgery if necessary (6) .
Induction CRT with S-1 plus cisplatin consisted of two courses of S-1 (60 mg/m 2 /day) administered p.o. or via PEG tube twice daily for 2 weeks and cisplatin infused on Days 8 through 11 every 5 weeks, plus 70 Gy radiation over 33-35 fractions. Table 1 shows the induction S-1/cisplatin course and modifications due to different toxicities. Cisplatin alone was reduced in cases of neurotoxicity.
Creatinine clearance (CCr) was calculated at the beginning of each course according to the Cockcroft-Graft formula. CCr values >60 ml/min required no dose modification; those ranging from 50 to <60 ml/min were addressed by a reduction in both S-1 and cisplatin of one dose level ( Table 1 , level 2). Patients with values of 40-50 ml/min were given doses of both S-1 and cisplatin at Level 3 ( Table 1 , Level 3). CCr <40 ml/min required the cessation of both S-1 and cisplatin.
Radiotherapy treatment was determined using an intensitymodulated radiotherapy treatment (IMRT) planning system. A radiation dose of 70 Gy in 33-35 fractions was given concurrently. Tumor responses were evaluated according to the RECIST criteria (7) .
Adjuvant chemotherapy with S-1 plus cisplatin was administered for two more courses in patients with an objective complete response (CR); good partial response (PR) (characterized as a secondary change unique to post-CRT that is regarded as residual scar without residual tumor, and defined as lesions ≤10 mm in size or not enhancing on contrast-enhanced CT) or PR at the first evaluation after CRT.
Adjuvant chemotherapy S-1 (60 mg/m 2 /day, adjusted for body surface area and toxicities) was orally administered for 2 weeks and cisplatin (20 mg/m 2 /day) was infused on Days 8 through 11, with one course repeat after 4 weeks. At the second evaluation after adjuvant chemotherapy, patients with CR or good PR were regarded as having completed the protocol. Patients not in the CR or good PR categories discontinued treatment, and salvage surgery was planned if it was judged clinically feasible.
Radiation therapy
IMRT was administered with high-energy photons of 4-10 MV for a total dose of 70 Gy in fractions of 2 Gy five times weekly. The gross tumor volume (GTV) included both the primary tumor and cervical lymph nodes with a short axis of 1 cm or larger. Clinical target volume 1 (CTV1) included the GTV and bilateral regional cervical lymph nodes with a 1-2 cm margin; and CTV2 included the GTV with a 0.5-2 cm margin. The planning target volumes (PTVs) for CTV1 and CTV2 (PTV1 and PTV2) were defined with 0.5-1 cm margins around the CTV. A total of 40 Gy was delivered to the PTV1, with an additional 30 Gy to PTV2.
Evaluation and follow-up
All enrolled patients were followed up for at least 3 years. Efficacy and safety were evaluated at least every 3 months during the first year, at least every 4 months during the second year and then every 6 months during the third year. Data on the use and methodology of nutritional support were reported at 2, 6, 12 and 24 months after registration.
Toxicity assessment
Toxicity was assessed by National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 and response to treatment was assessed by the RECIST criteria (8) .
Endpoint
Pharmacokinetic studies Blood was drawn from all patients on Day 7 of the first course of CRT. For patients requiring a reduction in S-1 dose due to toxicity, blood samples for pharmacokinetics were drawn the seventh day after dose reduction. When the dose of S-1 did not need to be reduced, blood specimens for pharmacokinetics were drawn on Day 7 of the adjuvant chemotherapy courses. Blood samples (2 ml) were collected in heparinized tubes before and 1, 2, 4, 8 and 10 hours after the administration of S-1. Plasma was separated by centrifugation and stored at −20°C until analysis.
Plasma concentrations of 5-FU were determined using gas chromatography-negative ion chemical ionization mass spectrometry. Pharmacokinetic parameters, including maximum plasma concentration at steady state (C ss max ), time to reach C ss max (T max ), area under the plasma concentration-versus-time curve from time 0-10 hours and from zero to infinity at steady state (AUC ss 0-10 and AUC ss 0-∞ , respectively), and plasma elimination half time (T 1/2 ) were calculated using a non-compartmental model with commercial software (Phenix ® WinNonlin ® Version 6.3, Pharsight Corporation, St. Louis, MO, USA). The primary endpoint was the change in the AUC ss 0-10 value of 5-FU.
Statistical analysis
Summary statistics, such as mean and standard deviation calculations, were performed for all pharmacokinetic parameters on all samples. Alterations in the pharmacokinetics of 5-FU were evaluated by applying paired t-tests to log-transformed means for each parameter (excluding T max ) to compare parameters between full and any reduced doses during the first course and between the first course and the adjuvant courses. Differences in T max between the induction course and after adjuvant course were evaluated using the Wilcoxon rank test for paired data. To evaluate the dose adjustment based on the CCr, differential analysis of comparison of pharmacokinetic parameters of 5-FU was conducted on subjects with alterations in renal function between the first course and after the second adjuvant course. Data storage and statistical analyses were carried out using commercial software (SAS version 9.2 software ® , SAS Institute, Inc., Cary, NC, USA).
Results

Patient characteristics
From July 2010 to January 2014, a total of 12 patients were enrolled. Patient characteristics are shown in Table 2 . The histology was squamous cell carcinoma in 11 patients and non-keratinizing carcinoma in one patient with nasopharyngeal carcinoma. Eleven patients completed treatment and went on to receive adjuvant chemotherapy. One patient died from aspiration pneumonia, which was not considered treatment-related. Five patients (46%) required a dose reduction of S-1, two patients suffered mucositis, two patients experienced renal dysfunction and one patient experienced febrile neutropenia. Pharmacokinetics and pharmacodynamics Plasma concentration-time profiles of 5-FU on Day 7 in courses 1 and 2 showed in Fig. 1 , and pharmacokinetic parameters after the first and second courses of 5-FU are summarized in Table 3 . C ss max , AUC ss 0-10 , the elimination rate constant T 1/2 and T max were similar between course 1 (during CRT) and course 2 (adjuvant chemotherapy) in six patients requiring no reduction in S-1 dose, and their plasma concentration-time profiles of 5-FU on Day 7 of the first and second course were almost superimposable 1 (Fig. 1A) .
Five patients required a reduction in S-1 dose. Analysis of kel and T max were similar between the first and second courses. However, the mean C ss max , AUC ss 0-10 and AUC ss∞ decreased by 69.7%, 71.8% and 73.6%, respectively. Plasma concentration-time profiles of 5-FU on Day 7 of the second course in three patients without renal impairment requiring S-1 dose reduction were obviously lower (Fig. 1B) .
In these five patients requiring a reduced S-1 dose, two patients developed renal insufficiency ( Table 3 ). The two patients with mucositis received a reduced level 2 of S-1 and the patient with febrile neutropenia required reduction of level 2 of S-1 and CDDP.
We compared the alterations in pharmacokinetics of 5-FU after S-1 dose reduction between patients with and without renal insufficiency. Although S-1 dose reduction did not affect the pharmacokinetic parameters of kel and T max in both patients without renal insufficiency, the mean AUC ss0-10 of 5-FU decreased significantly, by 55.3% (P = 0.0264) in the three patients without renal insufficiency. On the other hand, plasma concentration levels of 5-FU on Day 7 of the second course in the two patients with renal impairment requiring S-1 dose reduction showed similar profiles to those of the first course (Fig. 1C) , and C ss max and AUC ss 0-10 of 5-FU of the second course were also comparable to those of the first course (Table 3) .
Discussion
The standard treatment for unresectable SCCHN is cisplatin-based CRT (9, 10) . A phase I study of CRT with S-1 plus cisplatin in patients with unresectable locally advanced SCCHN showed a high CR rate (86%), while the completed phase II trial by the Japan Clinical Oncology Group (JCOG0706) showed a clinical complete remission rate of 64.4% (11) .
S-1 is an oral fluorinated pyrimidine combination, which was developed in an effort to further enhance the therapeutic index of FT. The plasma concentration of CDHP on S-1 administration correlates with the plasma concentration of 5-FU (1). This is because CDHP inhibits DPD, the rate limiting enzyme of 5-FU. Because 50% of CDHP is excreted in the urine, renal dysfunction strongly influences the level of 5-FU and its tendency to raise the plasma levels of 5-FU may cause adverse reactions. Thus, it is particularly important to frequently measure plasma 5-FU levels in patients with renal insufficiency or toxicity. Although the AUC of 5-FU can predict response or toxicity (12, 13) , appropriate criteria for reducing S-1 dosage have not been determined.
In a phase I study, all four patients whose CCr decreased to <60 ml/min after the first course of chemotherapy developed febrile neutropenia lasting >4 days (4). However, changes in plasma concentrations of 5-FU and in the pharmacokinetics of S-1 between initial and modified doses in patients with reduced CCr who require dosage change have not been reported.
In order to assess plasma concentrations of 5-FU, we evaluated the pharmacokinetics/pharmacodynamics after the first (full dose) and second (decreased dose) in patients with renal and non-renal toxicities. Results showed the expected decrease in levels in patients with non-renal toxicities versus little or no change in patients receiving a decreased dose due to renal toxicity.
Eleven of 12 patients could be evaluated in our study. Five patients required reductions in S-1, including two patients with renal insufficiency, two with mucositis and one with febrile neutropenia. Three patients had their S-1 dose decreased to 40 mg/m 2 for the second course of chemoradiotherapy (CRT). One patient with febrile neutropenia had cisplatin reduced to 16 mg/m 2 for the second course of CRT.
*1, P = 0.0458; *2, P = 0.0264; *3, P = 0.0272.
In the two patients with renal insufficiency, mean AUC ss 0-10 was not significantly changed. In the three patients without renal dysfunction receiving reduced doses, mean 5-FU AUC ss 0-10 was significantly decreased, by 55.3% (P = 0.0264). This study is limited due to only a small number of patients being included in this trial, with only two patients with renal insufficiency. Larger studies will be needed to see if our preliminary findings and the findings of other researchers are borne out.
Conclusions
Changes in the exposure to 5-FU at steady state were presumed to be lower in subjects receiving a reduced S-1 dose due to renal impairment; in this study, however, this was not the case. Paradoxically, 5-FU exposures at steady state in subjects after reduction of S-1 dose for renal toxicity did not change from those before dose reduction. We suggest that being aware of the unusual pharmacokinetics of S-1 in S-1 plus cisplatin combination therapy in patients with renal insufficiency may lower the risk of myelosuppression and other toxicities. The effects of cisplatin and radiation also need to be taken into account.
Since the study included only two subjects receiving an S-1 dose reduction due to renal impairment, further studies with a larger number of patients are needed to evaluate the pharmacokinetic parameters in subjects with renal impairment.
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